$5.180
+0.285 (+5.50%)收盤時
價格預測
在 App 中開啟以解鎖更長週期的預測。
MCRB 相似圖表分析預測
Alphio's MCRB stock price prediction model matches the current Seres Therapeutics Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $5.21 (+0.53%). The 1-week path is $5.42 (+4.68%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
該買進 Seres Therapeutics Inc 股票嗎?
Seres Therapeutics Inc is a good buy right now, primarily due to its recent financial turnaround, reporting a net income of $4.6 million in Q2 2026, which translates to $0.47 per share, a significant improvement from a net loss of $19.9 million in the same quarter last year. Additionally, the stock has shown a positive momentum with a 5-day change of +12.06% and an RSI of 66.737, indicating strong buying pressure. However, a key risk is the company's high forward P/E ratio of 10.82, which suggests that the stock may be overvalued if future earnings do not meet expectations.
MCRB 股價於 Tuesday 收在 $5.18,此前上漲 +5.50%
Seres Therapeutics Inc (MCRB) last closed at $5.18, gaining +5.50%. These facts feed the 1-day and 1-week MCRB price prediction above.
分析師一致預期
Seres Therapeutics Inc(MCRB):買進 7、持有 2、賣出 0。展望:Buy。
Sell / Buy
Technical signals summary based on buy and sell indicators. The gauge shows the overall market view.
預測驅動因素
Seres Therapeutics Inc(MCRB)的預測驅動因素綜合了相似的圖表形態、季節性與移動平均線。
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bullish
SMA 200
Bearish
相似圖表形態
近期走勢與 MCRB 最接近的股票,依相似度排序。
MCRB 季節性分析
Historically the probability of a positive September return for MCRB is 42.86%. October offers the highest probability of a positive month at 45.65%, while March is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。